Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

Form 4

February 27, 2015

FORM 4	l								OMB AP	PROVAL		
	UNITED	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								3235-0287		
Check this box if no longer									Expires:	January 31 2005		
subject to Section 16. Form 4 or Form 5 obligations	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,							e Act of 1934,	Estimated average burden hours per response 0			
may continue. See Instruction 1(b).		` '		tility Holovestment	_		•	1935 or Section 0	l			
(Print or Type Respo	onses)											
1. Name and Address of Reporting Person * McCorkle Douglas S			2. Issuer Name and Ticker or Trading Symbol					5. Relationship of Reporting Person(s) to Issuer				
			REGENERON PHARMACEUTICALS INC					(Check all applicable)				
			[REGN]					Director 10% Owner				
(Last)	(First) (rst) (Middle) 3. Date of Earliest Transactio (Month/Day/Year)						_X_ Officer (give below) VP Control	e title Other (specify below) oller and Asst Treasur			
777 OLD SAW ROAD	MILL RIVE	ER	02/27/2	015				VI Common	ioi una risst ri	Cusur		
				4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
TARRYTOWN	, NY 10591							Form filed by M Person	ore than One Rep	porting		
(City)	(State)	(Zip)	Tabl	le I - Non-I	Derivative	Secur	ities Acqu	uired, Disposed of,	or Beneficiall	y Owned		
	ransaction Date onth/Day/Year)		Date, if	3. Transactic Code (Instr. 8)	(Instr. 3,	sposed 4 and : (A) or	of (D) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common				Coue V	Amount	(D)	Price \$	4 404				

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

S

3,000

D

(1)

416.24 4,481

02/27/2015

Stock

Stock

Common

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control

4,129

D

I

By 401(k)

Plan

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Title	e and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	onNumber Expiration Date		ate	Amour	nt of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Underl	ying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securit	ties	(Instr. 5)	Bene
	Derivative				Securities			(Instr.	3 and 4)		Owne
	Security				Acquired						Follo
					(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									Amount		
									Amount		
					Date	Expiration Date	or Title Number				
					Exercisable						
				C 1 W	(A) (D)				of		
				Code V	(A) (D)				Shares		

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

McCorkle Douglas S 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591

VP Controller and Asst Treasur

Signatures

/s/**Douglas S. 02/27/2015 McCorkle

**Signature of Reporting Date
Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents volume-weighted average price of sales of 3,000 shares of Company stock on February 27, 2015 at prices ranging from (1) \$416.00 to \$416.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2015 at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2